SciClone Reaches Agreement to Settle FCPA Derivative Suit

The suit — a consolidation of four similar plaintiff’s actions — alleged the Foster City, Calif.-based drugmaker made material misstatements about its financial results based on allegedly illegal and improper sales and marketing activities of hepatitis drug Zadaxin in China.

This story is exclusively for members of the
JUST ANTI-CORRUPTION COMMUNITY
Log-in
E-mail Address or UserName: *
Password: *
Subscribe
Click here to subscribe to
Just Anti-Corruption


For information about pricing, click here.
Ernst & Young LLP
Dealing with complex issues of fraud, regulatory compliance and business disputes can detract from efforts to succ... more
Covington & Burling LLP
ANALYSIS: The UK Government’s New Anti-Corruption Plan more
Sheppard, Mullin, Richter & Hampton LLP
ANALYSIS: Never Let Them See You Coming—Keys to Setting Up Witnesses Interviews In An Internal Investigation more
Skadden, Arps, Slate, Meagher & Flom LLP
ANALYSIS: International Cooperation, Anti-Corruption and Tax Remain Key Issues for U.S. Enforcement Authorities more
A&L Goodbody
ANALYSIS: Preparing Your Business for Ireland's Impending Anti-Bribery Laws  more
Taft Stettinius & Hollister LLP
ANALYSIS: Chinese President and SEC/DOJ Send the Same Message - Reinforce Your Chinese Anti-Corruption Compli... more
Proskauer Rose LLP
ANALYSIS: U.S. Sentencing Commission Proposes Amendments to Widely Criticized Economic Crime Sentencing Guide... more

Watch Day Two of Attorney General nominee Loretta Lynch's Senate confirmation hearing.